Advertisement

Human Cell

, Volume 33, Issue 1, pp 195–204 | Cite as

LncRNA LINC00857 regulates lung adenocarcinoma progression, apoptosis and glycolysis by targeting miR-1179/SPAG5 axis

  • Lan Wang
  • Liqiang Cao
  • Chunxia Wen
  • Jie Li
  • Guiping Yu
  • Chengying LiuEmail author
Research Article
  • 66 Downloads

Abstract

Long non-coding RNA (lncRNA), a member of non-coding RNA family with over 200 nucleotides in length, typically serves as an oncogene or tumor suppressor in tumor progression, such as cancer cell proliferation, apoptosis and glycolysis. Recent studies manifested lncRNA LINC00857 was involved in cell cycle regulation of lung cancer. Due to complicated networks in tumorigenesis, the potential roles of LINC00857 underlying lung cancer progression still need further investigation. In this study, we explored the expression of LINC00857 in lung adenocarcinoma (LUAD) tissues and LUAD cell lines and found a dramatical upregulation of LINC00857 compared with the adjacent normal lung tissues and BEAS-2B cell line, respectively. Then, LINC00857 knockdown led to the cell proliferation and glycolysis was repressed, while the apoptosis was elevated in LUAD cell lines. Furthermore, we identified a direct interaction between LINC00857 and miR-1179 in LUAD cells using bioinformatic method and report assay. Finally, we evidenced LINC00857 promoted cell growth and glycolysis and repressed apoptosis via sponging miR-1179 and further regulating sperm-associated antigen 5 (SPAG5) expression in LUAD cell lines. Hence, our results authenticated that lncRNA LINC00857 regulated the cell proliferation, glycolysis and apoptosis of LUAD cells mainly through targeting the miR-1179/SPAG5 axis, which might be a novel insight into lung cancer progression and provided a potential target for clinical treatment of LUAD patients.

Keywords

LINC00857 Lung adenocarcinoma Proliferation Glycolysis Apoptosis 

Notes

Acknowledgements

We thank all the staff at the Department of Respiratory and Critical Care Medicine, the Affiliated Jiangyin Hospital of Southeast University Medical College. This work was supported by Clinical Medical Science and Technology Development Fund Project of Jiangsu University (JLY20180184).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The study was approved by the ethics committee of Jiangyin Hospital (Approval number: 2018024).

Supplementary material

13577_2019_296_MOESM1_ESM.docx (19 kb)
Supplementary material 1 (DOCX 19 kb)

References

  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA. 2019;69(1):7–34.  https://doi.org/10.3322/caac.21551.CrossRefPubMedGoogle Scholar
  2. 2.
    Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008;455(7216):1069–75.  https://doi.org/10.1038/nature07423.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Dhanasekaran SM, Alejandro Balbin O, Chen G, Nadal E, Kalyana-Sundaram S, Pan J, et al. Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes. Nat Commun. 2014;5(1):5893.  https://doi.org/10.1038/ncomms6893.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359(13):1367–80.  https://doi.org/10.1056/NEJMra0802714.CrossRefPubMedGoogle Scholar
  5. 5.
    Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D, et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature. 2009;458(7235):223–7.  https://doi.org/10.1038/nature07672.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Prensner JR, Iyer MK, Balbin OA, Dhanasekaran SM, Cao Q, Brenner JC, et al. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol. 2011;29(8):742–9.  https://doi.org/10.1038/nbt.1914.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Balbin OA, Malik R, Dhanasekaran SM, Prensner JR, Cao X, Wu Y-M, et al. The landscape of antisense gene expression in human cancers. Genome Res. 2015;25(7):1068–79.  https://doi.org/10.1101/gr.180596.114.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Huang Y, Liu N, Wang JP, Wang YQ, Yu XL, Wang ZB, et al. Regulatory long non-coding RNA and its functions. J Physiol Biochem. 2012;68(4):611–8.  https://doi.org/10.1007/s13105-012-0166-y.CrossRefPubMedGoogle Scholar
  9. 9.
    Batista Pedro J, Chang Howard Y. Long noncoding RNAs: cellular address codes in development and disease. Cell. 2013;152(6):1298–307.  https://doi.org/10.1016/j.cell.2013.02.012.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Carpenter S, Aiello D, Atianand MK, Ricci EP, Gandhi P, Hall LL, et al. A long noncoding RNA mediates both activation and repression of immune response genes. Science. 2013;341:789–92.CrossRefGoogle Scholar
  11. 11.
    Wahlestedt C. Targeting long non-coding RNA to therapeutically upregulate gene expression. Nat Rev Drug Discov. 2013;12(6):433–46.  https://doi.org/10.1038/nrd4018.CrossRefPubMedGoogle Scholar
  12. 12.
    Yang F, Huo X-S, Yuan S-X, Zhang L, Zhou W-P, Wang F, et al. Repression of the long noncoding RNA-LET by histone deacetylase 3 contributes to hypoxia-mediated metastasis. Mol Cell. 2013;49(6):1083–96.  https://doi.org/10.1016/j.molcel.2013.01.010.CrossRefPubMedGoogle Scholar
  13. 13.
    Yang L, Lin C, Jin C, Yang JC, Tanasa B, Li W, et al. lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs. Nature. 2013;500(7464):598–602.  https://doi.org/10.1038/nature12451.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Huarte M, Guttman M, Feldser D, Garber M, Koziol MJ, Kenzelmann-Broz D, et al. A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell. 2010;142(3):409–19.  https://doi.org/10.1016/j.cell.2010.06.040.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Tripathi V, Ellis JD, Shen Z, Song DY, Pan Q, Watt AT, et al. The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol Cell. 2010;39(6):925–38.  https://doi.org/10.1016/j.molcel.2010.08.011.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Guttman M, Donaghey J, Carey BW, Garber M, Grenier JK, Munson G, et al. LincRNAs act in the circuitry controlling pluripotency and differentiation. Nature. 2011;477(7364):295–300.  https://doi.org/10.1038/nature10398.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Clurman BE, Tripathi V, Shen Z, Chakraborty A, Giri S, Freier SM, et al. Long noncoding RNA MALAT1 controls cell cycle progression by regulating the expression of oncogenic transcription factor B-MYB. PLoS Genet. 2013;9(3):e1003368.  https://doi.org/10.1371/journal.pgen.1003368.CrossRefGoogle Scholar
  18. 18.
    Yu L, Chen X, Sun X, Wang L, Chen S. The glycolytic switch in tumors: how many players are involved? J Cancer. 2017;8(17):3430–40.  https://doi.org/10.7150/jca.21125.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Liu X, Zhu Q, Guo Y, Xiao Z, Hu L, Xu Q. LncRNA LINC00689 promotes the growth, metastasis and glycolysis of glioma cells by targeting miR-338-3p/PKM2 axis. Biomed Pharmacother. 2019;117:109069.  https://doi.org/10.1016/j.biopha.2019.109069.CrossRefPubMedGoogle Scholar
  20. 20.
    Wang Y, Yang L, Chen T, Liu X, Guo Y, Zhu Q, et al. A novel lncRNA MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by targeting miR-194-5p/FOXA1 axis. Mol Cancer. 2019;18(1):28.  https://doi.org/10.1186/s12943-019-0957-7.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Changyong E, Yang J, Li H, Li C. LncRNA LOC105372579 promotes proliferation and epithelial-mesenchymal transition in hepatocellular carcinoma via activating miR-4316/FOXP4 signaling. Cancer Manag Res. 2019;11:2871–9.  https://doi.org/10.2147/cmar.s197979.CrossRefGoogle Scholar
  22. 22.
    Wang L, He Y, Liu W, Bai S, Xiao L, Zhang J, et al. Non-coding RNA LINC00857 is predictive of poor patient survival and promotes tumor progression via cell cycle regulation in lung cancer. Oncotarget. 2016;7(10):11487–99.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16:203.  https://doi.org/10.1038/nrd.2016.246. https://www.nature.com/articles/nrd.2016.246#supplementary-information.CrossRefGoogle Scholar
  24. 24.
    Zhang B, Pan X, Cobb GP, Anderson TA. MicroRNAs as oncogenes and tumor suppressors. Dev Biol. 2007;302(1):1–12.  https://doi.org/10.1016/j.ydbio.2006.08.028.CrossRefPubMedGoogle Scholar
  25. 25.
    Shenouda SK, Alahari SK. MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev. 2009;28(3–4):369–78.  https://doi.org/10.1007/s10555-009-9188-5.CrossRefPubMedGoogle Scholar
  26. 26.
    Ameres SL, Zamore PD. Diversifying microRNA sequence and function. Nat Rev Mol Cell Biol. 2013;14:475.  https://doi.org/10.1038/nrm3611.CrossRefPubMedGoogle Scholar
  27. 27.
    Vidigal JA, Ventura A. The biological functions of miRNAs: lessons from in vivo studies. Trends Cell Biol. 2015;25(1879–3088 (Electronic)):137–47.CrossRefGoogle Scholar
  28. 28.
    Jiang L, Wang Y, Rong Y, Xu L, Chu Y, Zhang Y, et al. miR-1179 promotes cell invasion through SLIT2/ROBO1 axis in esophageal squamous cell carcinoma. Int J Clin Exp Pathol. 2015;8(1):319–27.PubMedPubMedCentralGoogle Scholar
  29. 29.
    Xu X, Cai N, Zhi T, Bao Z, Wang D, Liu Y, et al. MicroRNA-1179 inhibits glioblastoma cell proliferation and cell cycle progression via directly targeting E2F transcription factor 5. Am J Cancer Res. 2017;7(8):1680–92.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Song L, Dai Z, Zhang S, Zhang H, Liu C, Ma X, et al. MicroRNA-1179 suppresses cell growth and invasion by targeting sperm-associated antigen 5-mediated Akt signaling in human non-small cell lung cancer. Biochem Biophys Res Commun. 2018;504(1):164–70.  https://doi.org/10.1016/j.bbrc.2018.08.149.CrossRefPubMedGoogle Scholar
  31. 31.
    An J, Shi H, Zhang N, Song S. Elevation of circular RNA circ_0003645 forecasts unfavorable prognosis and facilitates cell progression via miR-1179/TMEM14A pathway in non-small cell lung cancer. Biochem Biophys Res Commun. 2019;511(4):921–5.  https://doi.org/10.1016/j.bbrc.2019.03.011.CrossRefPubMedGoogle Scholar
  32. 32.
    Liberti MV, Locasale JW. The warburg effect: how does it benefit cancer cells? Trends Biochem Sci. 2016;41(3):211–8.  https://doi.org/10.1016/j.tibs.2015.12.001.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Japan Human Cell Society and Springer Japan KK, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Respiratory and Critical Care MedicineThe Affiliated Jiangyin Hospital of Southeast University Medical CollegeJiangyinChina
  2. 2.Medical School and Jiangsu Key Laboratory of Molecular MedicineNanjing UniversityNanjingChina
  3. 3.Department of Cardiothoracic SurgeryThe Affiliated Jiangyin Hospital of Southeast University Medical CollegeJiangyinChina

Personalised recommendations